Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

This study has been completed.

Sponsor:

Information provided by:

Forest Laboratories

ClinicalTrials.gov Identifier:

NCT00112190

First received: May 31, 2005

Last updated: February 6, 2017

Last verified: February 2017

History of Changes

Purpose

Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms of functional dyspepsia. Patients suffering from this condition have difficulties digesting food. They feel full after eating a few bites; they feel bloated and their stomachs hurt. The goal of this study is to see if itopride helps to relieve the symptoms of functional dyspepsia.

Condition	Intervention	Phase
Dyspepsia	Drug: Itopride Hydrochloride Drug: itopride	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Multicentre, Randomized, Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Itopride HCl in Patients Suffering From Functional Dyspepsia

Resource links provided by NLM:

MedlinePlus related topics: Indigestion

U.S. FDA Resources

Further study details as provided by Forest Laboratories:

Primary Outcome Measures:

Symptom relief

Secondary Outcome Measures:

Impact of symptom relief on quality of life
Safety


Enrollment:	645
Study Start Date:	July 2004
Study Completion Date:	March 2006
Primary Completion Date:	March 2005 (Final data collection date for primary outcome measure)

Intervention Details:

100 mg tid

100 mg three times daily

Detailed Description:

The study lasts approximately 10 weeks. Patients may either receive the real itopride, or a sugar pill called placebo. They have equal chances of receiving either treatment. After having completed this study, patients may be eligible to continue treatment for a longer period. At that point, all patients receive itopride.

Patients need to come to the clinic for evaluations 4 times during the trial. Various evaluations are done at these visits, such as a physical exam, lab tests, evaluation of the heart condition, and questionnaires need to be completed by the patient to see if the drug helps them in relieving their symptoms.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients suffering from functional dyspepsia according to Rome II criteria
- 18-65 years old
- Absence of, or infrequent heartburn (one episode per week or less)
- Helicobacter pylori (H. pylori) negative
- Normal upper endoscopy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00112190

Locations


Canada, Quebec
AXCAN Pharma Inc.
Mont St-Hilaire, Quebec, Canada, J3H 6C4

Sponsors and Collaborators

Forest Laboratories

Investigators


Principal Investigator:	Nicholas Talley, MD	Mayo Clinic, Rochester, Minn

More Information


Responsible Party:	Dr. N. Talley, Mayo Clinic
ClinicalTrials.gov Identifier:	NCT00112190 History of Changes
Other Study ID Numbers:	ITOFD04-01
Study First Received:	May 31, 2005
Last Updated:	February 6, 2017

Keywords provided by Forest Laboratories:


Functional dyspepsia Abdominal Symptom relief Fullness Bloating Indigestion

Additional relevant MeSH terms:


Dyspepsia Signs and Symptoms, Digestive Signs and Symptoms

ClinicalTrials.gov processed this record on August 18, 2017

To Top